1 / 7

Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0 .

Could an antianginal metabolic agent have an impact on prognosis in ischemic patients ? Beneficial effects of trimetazidine in patients with acute myocardial infarction. Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0. Impact of trimetazidine on prognosis. Methods

coyne
Download Presentation

Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0 .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Could an antianginal metabolic agent have an impact on prognosisin ischemic patients?Beneficial effects of trimetazidinein patients with acute myocardial infarction Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  2. Impact of trimetazidine on prognosis • Methods • Among the 13 000 AMI patients involved in the large-scale, prospective, observational Korean Acute Myocardial Infarction Registry (KAMIR), those receiving trimetazidinewere included in the present analysis. • Two groups: patients treated with trimetazidine (either the 20 mg tablet or the 35 mg modified-release tablet) during their in-hospital management period and patients who were not. • A propensity score analysis was performed to equilibrate the 2 groups. • 75% received -blockers, 90% statins, and 90% ACE inhibitors/ARBs. • Primary end points: all-cause death and major adverse cardiac events (MACE), which included all-cause death, recurrent myocardial infarction, repeat PCI for target lesion revascularization, and CABG. Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  3. Impact of trimetazidine on prognosis All results Trimetazidine Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  4. Impact of trimetazidine on prognosis Results on MACE Trimetazidine Control One year MACE: all-cause death, recurrentmyocardialinfarction, repeated PCI for target lesion revascularization, and CABG. Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  5. Impact of trimetazidine on prognosis Results on all-cause death Trimetazidine Trimetazidine Control Control One year Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  6. Impact of trimetazidine on prognosis Discussion TMZ = Trimetazidine Kim JS et al. Clin Res Cardiol. DOI 10.1007/s00392-013-0611-0.

  7. Conclusion • Several previous clinical studies have already shown that trimetazidine may improve prognosis in heart failure and post-MI patients.1-3 • This new study demonstrates that patients who receive trimetazidine seem to live longer after an MI. • This cardiac protection against ischemia could be linked to the 33% energy increase provided by trimetazidine in cardiomyocytes. 1. Gao D et al. Heart. 97:278-286. 2. Fragasso G et al. Int J Cardiol . 163:320-325. 3. Iyengar SS et al. (METRO). Am J Cardiovasc Drugs. 9:293-297.

More Related